UPDATE: Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University
Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium
Scorpius Holdings, Inc. Announces Closing of Public Offering
Scorpius Holdings, Inc. Announces Pricing of Public Offering
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under "SCPX" Effective at the Market Open Today
NightHawk's Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.